Budget Amount *help |
¥24,180,000 (Direct Cost: ¥18,600,000、Indirect Cost: ¥5,580,000)
Fiscal Year 2018: ¥6,110,000 (Direct Cost: ¥4,700,000、Indirect Cost: ¥1,410,000)
Fiscal Year 2017: ¥6,110,000 (Direct Cost: ¥4,700,000、Indirect Cost: ¥1,410,000)
Fiscal Year 2016: ¥11,960,000 (Direct Cost: ¥9,200,000、Indirect Cost: ¥2,760,000)
|
Outline of Final Research Achievements |
Respiratory syncytial virus (RSV) vaccine is currently not available. In this study, we examined the induction mechanism of allergic responses after vaccination with RSV and type 2 immune response with RSV infection. First, it was revealed that growth arrest specific 6 produced by formalin fixed RSV induces type 2 immune response (allergic airway inflammation) via its receptor Axl. We also found that Axl inhibitor shift the immune response from type 2 to 1 and can be an adjuvant and also useful for the elimination of RSV.
|